LC–MS Determination of Gabapentin from Human Plasma
- 180 Downloads
- 7 Citations
Abstract
Gabapentin is an anticonvulsant drug used for the treatment of epilepsy. It is not bound to plasma protein and is not metabolized. A high performance liquid chromatography–mass spectrometric micro method is described in this report for its determination from human plasma. Chromatography was performed on a 50 × 4.6 mm, 4 μm nitrile column and the parent ion detected in the positive ionization mode on single quadrupole analyzer (Q1MI) with atmospheric pressure ionization source. Extraction was carried out on C18, 100 mg/3cc cartridge using 10 μL sample volume. The mean extraction recovery was 97% and within batch and between batch coefficients of variation were <9%. Lack of interference from endogenous substances helped in achieving a highly sensitive method without the need for monitoring fragment ions. The lowest concentration injected on column for calibration curve was 195 pg (range 0.5–64 ng). The method was applied for analysis of samples from a cross-over bio-equivalence study comparing two formulations.
Keywords
Column liquid chromatography–mass spectrometry Epilepsy treatment GabapentinReferences
- 1.Beydoun A, Uthman BM, Sackellars JC (1995) Clin Neuropharmacol 18:469–481CrossRefGoogle Scholar
- 2.To TP, Lim TC, Hill ST, Frauman AG, Cooper N, Kirsa SW et al (2002) Spinal Cord 40:282–285CrossRefGoogle Scholar
- 3.Mellegers MA, Furlan AD, Mailis A (2001) Clin J Pain 17:284–295CrossRefGoogle Scholar
- 4.Putzke JD, Richards JS, Kezar L, Hicken BL, Ness TJ (2002) Clin J Pain 18:116–121CrossRefGoogle Scholar
- 5.Berigan TR (2002) J Clin Psychiatry 63:744Google Scholar
- 6.Chen B, Stitik TP, Foye PM, Nadler SF, De Lisa JA (2002) Am J Phys Med Rehabil 81:718–720CrossRefGoogle Scholar
- 7.Gilron I (2002) Anesthesiology 97:537–539CrossRefGoogle Scholar
- 8.Rose MA, Kam PC (2002) Anaesthesia 57:451–462CrossRefGoogle Scholar
- 9.Bozikas V, Petrikis P, Gamvrula K, Savvidou I, Karavates A (2002) Prog Neuropsychopharmacol Biol Psychiatry 26:197–199CrossRefGoogle Scholar
- 10.Schoonman GG, Wiendels NJ, Ferrari MD (2002) Headache 42:235CrossRefGoogle Scholar
- 11.Jeffery SM, Pepe JJ, Popvich LM, Vitagliano G (2002) Ann Pharmacother 36:433–436CrossRefGoogle Scholar
- 12.Chandler A, Williams JE (2000) J Pain Symptom Manage 20:82–86CrossRefGoogle Scholar
- 13.Dirks J, Fredensborg BB, Christesen D, Fomsgard JS, Flyger H, Dahl JB (2002) Anesthesiology 97:560–564CrossRefGoogle Scholar
- 14.Hengy H, Kolle EU (1985) J Chromatogr 341:473–478CrossRefGoogle Scholar
- 15.Wad N, Kramer G (1998) J Chromatogr B Biomed Sci Appl 705:154–158CrossRefGoogle Scholar
- 16.Jiang Q, Li S (1999) J Chromatogr B Biomed Sci Appl 727:119–123CrossRefGoogle Scholar
- 17.Lensmeyer GL, Kempf T, Gidal BE, Wiebe DA (1995) Ther Drug Monit 17:251–258CrossRefGoogle Scholar
- 18.Forrest G, Sills GJ, Leach JP, Brodie MJ (1996) J Chromatogr B Biomed Sci Appl 681:421–425CrossRefGoogle Scholar
- 19.Tang OH, Miles MV, Glauser TA, De Grauw T (1999) J Chromatogr B Biomed Sci Appl 727:125–129CrossRefGoogle Scholar
- 20.Kushnir MM, Crossett J, Brown PI, Urry FM (1999) J Anal Toxicol 23:1–6Google Scholar
- 21.Wolf CE, Saady JJ, Polkis A (1996) J Anal Toxicol 20:498–501Google Scholar
- 22.Hooper WD, Kavanagh MC, Dickinson RG (1990) J Chromatogr 529:167–174CrossRefGoogle Scholar
- 23.Gambelunghe C, Mariucci G, Tantucci M, Ambrosini MV (2005) Biomed Chromatogr 19:63–67CrossRefGoogle Scholar
- 24.Garcia LL, Shihabi ZK, Oles K (1995) J Chromatogr B Biomed Sci Appl 669:157–162CrossRefGoogle Scholar
- 25.Ifa DR, Falci M, Moraes ME, Bezerra FA, Moraes MO, de Nucci G (2001) J Mass Spectrom 36:188–194CrossRefGoogle Scholar
- 26.Carlsson KC, Reubsaet JLE (2004) J Pharm Biomed Anal 34:415–423CrossRefGoogle Scholar
- 27.Matar KM, Abdel-Hamid ME (2005) Chromatographia 61:499–504CrossRefGoogle Scholar
- 28.Ji HY, Jeong DW, Kim YH, Kim HH, Yoon YS, Lee KC, Lee HS (2006) Rapid Commun Mass Spectrom 20:2127–2132CrossRefGoogle Scholar